Evidence map›Paper›PMID 37968732›Full record

ArticleNeurological research and practice2023

Symptomatic treatment options for Huntington's disease (guidelines of the German Neurological Society).

Carsten Saft, Jean-Marc Burgunder, Matthias Dose, Hans Heinrich Jung, Regina Katzenschlager, Josef Priller, Huu Phuc Nguyen, Kathrin Reetz, Ralf Reilmann, Klaus Seppi and 1 more

Open access · diamondAbstract read
In one paragraph

Article in Neurological research and practice, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 1 pooled it
4.2field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Observational
  14. Regulation ofInternational journal of molecular sciences · 2024
    Review
  15. Review
  16. Pathomechanisms of behavioral abnormalities in Huntington disease: an update.Journal of neural transmission (Vienna, Austria : 1996) · 2024
    Review
  17. Review
  18. Review
  19. TargetingInternational journal of molecular sciences · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 10 institutions in 3 countries.

Carsten SaftDepartment of Neurology, Huntington-Zentrum NRW, St. Josef-Hospital, Ruhr-Universität Bochum, Bochum, Germany. carsten.saft@ruhr-uni-bochum.de.ORCID http://orcid.org/0000-0002-3983-7292
Jean-Marc BurgunderDepartment of Neurology, Schweizerisches Huntington-Zentrum, Bern University, Bern, Switzerland.
Matthias DoseKbo-Isar-Amper-Klinikum, Taufkirchen/München-Ost, Germany.
Hans Heinrich JungDepartment of Neurology, Universitätsspital Zürich, Zürich, Switzerland.
Regina KatzenschlagerDepartment of Neurology and Karl Landsteiner Institute for Neuroimmunological and Neurodegenerative Disorders, Klinik Donaustadt, Vienna, Austria.
Josef PrillerDepartment of Psychiatry and Psychotherapy, Klinikum rechts der Isar, School of Medicine, Technical University of Munich, Munich, Germany.
Huu Phuc NguyenHuntington-Zentrum NRW, Department of Human Genetics, Ruhr-Universität Bochum, Bochum, Germany.
Kathrin ReetzDepartment of Neurology, Euregional Huntington Centre Aachen, RWTH Aachen University Hospital, Aachen, Germany.
Ralf ReilmannGeorge-Huntington-Institute, Muenster, Germany.
Klaus SeppiDepartment of Neurology, Medical University of Innsbruck, Innsbruck, Austria.
Georg Bernhard LandwehrmeyerDepartment of Neurology, Huntington's Disease Centre, Ulm University, Ulm, Germany.
Donauspital · ATHertie Institute for Clinical Brain Research · DEInnsbruck Medical University · ATIsar-Amper-Klinikum München-Ost · DERuhr University Bochum · DESt. Josef-Hospital · DETUM Klinikum · DEUniversitätsklinikum Aachen · DEUniversität Ulm · DEUniversity Hospital of Zurich · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionAmeliorating symptoms and signs of Huntington's disease (HD) is essential to care but can be challenging and hard to achieve. The pharmacological treatment of motor signs (e.g. chorea) may favorably or unfavorably impact other facets of the disease phenotype (such as mood and cognition). Similarly, pharmacotherapy for behavioral issues may modify the motor phenotype. Sometimes synergistic effects can be achieved. In patients undergoing pragmatic polypharmacological therapy, emerging complaints may stem from the employed medications' side effects, a possibility that needs to be considered. It is recommended to clearly and precisely delineate the targeted signs and symptoms (e.g., chorea, myoclonus, bradykinesia, Parkinsonism, or dystonia). Evidence from randomized controlled trials (RCTs) is limited. Therefore, the guidelines prepared for the German Neurological Society (DGN) for German-speaking countries intentionally extend beyond evidence from RCTs and aim to synthesize evidence from RCTs and recommendations of experienced clinicians. RECOMMENDATIONS: First-line treatment for chorea is critically discussed, and a preference in prescription practice for using tiapride instead of tetrabenazine is noted. In severe chorea, combining two antidopaminergic drugs with a postsynaptic (e.g., tiapride) and presynaptic mode of action (e.g., tetrabenazine) is discussed as a potentially helpful strategy. Sedative side effects of both classes of compounds can be used to improve sleep if the highest dosage of the day is given at night. Risperidone, in some cases, may ameliorate irritability but also chorea and sleep disorders. Olanzapine can be helpful in the treatment of weight loss and chorea, and quetiapine as a mood stabilizer with an antidepressant effect.

conclusionsSince most HD patients simultaneously suffer from distinct motor signs and distinct psychiatric/behavioral symptoms, treatment should be individually adapted.

Identifiers

PMID37968732
PMCPMC10652593
OpenAlexW4388714805

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.